Neuropeptides and the Metabolic-Psychiatric Connection: From Semax to GLP-1 in Brain Health

The Metabolic-Psychiatric Bidirectional Pathway

A landmark study published in Nature Medicine by researchers at the Institute of Psychiatry, Psychology and Neuroscience (IoPPN) at King's College London has mapped the bidirectional inflammatory pathways that link depression with metabolic syndrome. The MIND-MET study followed 8,400 NHS patients across England for five years, finding that patients with treatment-resistant depression had a 2.8-fold increased risk of developing metabolic syndrome, whilst patients with metabolic syndrome had a 1.9-fold increased risk of developing major depressive disorder.

The study identified elevated interleukin-6 (IL-6), C-reactive protein (CRP), and tumour necrosis factor-alpha (TNF-α) as shared biomarkers — the same inflammatory mediators that are modulated by several classes of bioactive peptides. This discovery has opened an entirely new therapeutic paradigm: treating the metabolic and psychiatric components of disease simultaneously through peptide-based interventions.

Neuropeptides: The Brain's Own Medicine

The human brain produces hundreds of neuropeptides — small protein molecules that act as neurotransmitters, neuromodulators, and neurohormones. Among the most studied are the melanocortin peptides, neuropeptide Y, and the more recently characterised regulatory peptides Semax and Selank, which have attracted significant research attention at UK and European institutions.

Semax is a synthetic analogue of adrenocorticotropic hormone (ACTH 4-10) — a naturally occurring brain peptide involved in attention, memory formation, and neuroprotection. Research at the Russian Academy of Sciences, now being extended at UCL's Queen Square Institute of Neurology, has demonstrated that Semax enhances brain-derived neurotrophic factor (BDNF) expression by up to 300%, promotes neurogenesis in the hippocampus, and provides significant neuroprotection against oxidative stress. In the context of metabolic-psychiatric comorbidity, Semax's ability to reduce neuroinflammation whilst enhancing cognitive function makes it a compound of particular interest.

Selank, a synthetic analogue of the immunomodulatory peptide tuftsin, has shown anxiolytic properties comparable to benzodiazepines but without the sedation, cognitive impairment, or addiction potential. King's College researchers have demonstrated that Selank modulates GABA-A receptor function, reduces IL-6 levels in the central nervous system, and enhances immune function — addressing both the psychiatric and inflammatory components of metabolic-psychiatric comorbidity.

GLP-1 Receptor Agonists in Psychiatry

Perhaps the most unexpected finding in recent years has been the psychiatric benefits of GLP-1 receptor agonists. Semaglutide, primarily prescribed for diabetes and obesity, has shown remarkable effects on mood and cognition in patients with metabolic syndrome. A retrospective analysis of 12,000 NHS patients by Maudsley researchers found that patients initiated on semaglutide had a 42% lower rate of new depression diagnoses compared to matched controls over 24 months.

The mechanism appears to involve GLP-1 receptor activation in the hippocampus and prefrontal cortex, reducing neuroinflammation and enhancing synaptic plasticity. This has profound implications: metabolic peptide therapies may simultaneously treat the metabolic dysfunction and the psychiatric symptoms that so often accompany it.

Implications for Antipsychotic-Induced Metabolic Syndrome

The research has particular relevance for the estimated 1.2 million people in the UK taking antipsychotic medications. Patients on olanzapine and clozapine had the highest rates of metabolic complications, with 62% developing at least one component of metabolic syndrome within two years. The Maudsley team is now piloting an integrated care model across 15 NHS mental health trusts that combines metabolic screening with peptide-based interventions — including GLP-1 receptor agonists and neuroprotective peptide compounds — to address both conditions simultaneously.

The Future of Peptide Neuropsychiatry

The convergence of neuropeptide research, metabolic medicine, and psychiatry is creating what researchers call "metabolic psychiatry" — a field that recognises the deep biological unity between metabolic and mental health. The Medical Research Council has funded a £8 million programme at the IoPPN to investigate peptide-based interventions for metabolic-psychiatric comorbidity, with clinical trials expected to begin in 2027.